GSK PLC Sponsored ADR (NYSE:GSK) Given Consensus Rating of “Reduce” by Analysts

Shares of GSK PLC Sponsored ADR (NYSE:GSK) have earned a consensus recommendation of “Reduce” from the ten analysts that are covering the stock, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $53.00.

GSK has been the subject of several recent analyst reports. Citigroup reaffirmed a “neutral” rating on shares of GSK in a report on Monday, February 9th. Weiss Ratings lowered GSK from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 19th. Wall Street Zen lowered GSK from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 7th. Morgan Stanley reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 14th. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of GSK in a report on Friday, January 16th.

Hedge Funds Weigh In On GSK

Several institutional investors and hedge funds have recently bought and sold shares of the company. IHT Wealth Management LLC grew its holdings in GSK by 1.3% during the fourth quarter. IHT Wealth Management LLC now owns 15,010 shares of the pharmaceutical company’s stock valued at $736,000 after purchasing an additional 188 shares during the period. Bogart Wealth LLC grew its holdings in GSK by 15.3% during the first quarter. Bogart Wealth LLC now owns 1,508 shares of the pharmaceutical company’s stock valued at $83,000 after purchasing an additional 200 shares during the period. Coston McIsaac & Partners grew its holdings in GSK by 17.3% during the fourth quarter. Coston McIsaac & Partners now owns 1,395 shares of the pharmaceutical company’s stock valued at $68,000 after purchasing an additional 206 shares during the period. First Horizon Corp grew its holdings in GSK by 78.7% during the fourth quarter. First Horizon Corp now owns 536 shares of the pharmaceutical company’s stock valued at $26,000 after purchasing an additional 236 shares during the period. Finally, Peoples Bank KS grew its holdings in GSK by 6.3% during the fourth quarter. Peoples Bank KS now owns 5,030 shares of the pharmaceutical company’s stock valued at $247,000 after purchasing an additional 300 shares during the period. 15.74% of the stock is owned by institutional investors.

GSK Stock Performance

GSK stock opened at $51.65 on Monday. The firm has a market cap of $104.80 billion, a PE ratio of 13.41, a P/E/G ratio of 2.67 and a beta of 0.38. The company has a quick ratio of 0.54, a current ratio of 0.79 and a debt-to-equity ratio of 0.80. The business has a 50 day moving average of $55.78 and a 200-day moving average of $51.62. GSK has a 12-month low of $35.45 and a 12-month high of $61.69.

GSK (NYSE:GSK) last released its earnings results on Thursday, February 5th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.04. The company had revenue of $11.59 billion during the quarter, compared to analyst estimates of $8.48 billion. GSK had a return on equity of 44.28% and a net margin of 17.82%.GSK’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.23 earnings per share. As a group, sell-side analysts expect that GSK will post 4.88 earnings per share for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 9th. Shareholders of record on Friday, May 15th will be issued a dividend of $0.44 per share. This represents a $1.76 annualized dividend and a yield of 3.4%. The ex-dividend date of this dividend is Friday, May 15th. GSK’s dividend payout ratio is 50.81%.

Key Headlines Impacting GSK

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK announced a quarterly dividend of $0.44 per share (annualized yield ~3.4%), with shareholders of record May 15 and payment scheduled July 9 — a cash-return signal that tends to support the share price and income-oriented investors.
• Positive Sentiment: GSK Canada secured priority review for bepirovirsen, a potential functional cure therapy for chronic hepatitis B — regulatory progress on a high-value asset could be a meaningful mid/long-term value driver if approved. GSK Canada priority review
• Positive Sentiment: Q1 2026 results showed solid sales growth (~5%) led by specialty medicines and vaccines and management highlighted strategic pipeline expansion — the quarter reinforced underlying cash flow and earnings stability. Q1 2026 earnings call highlights
• Neutral Sentiment: Analyst commentary and value screens highlight GSK as a long-term value pick for some investors (Zacks coverage), which can attract longer-horizon buyers but may have limited near-term price impact. Zacks analysis
• Negative Sentiment: GSK-partnered Alzheimer’s asset from Alector failed its Phase 2 study — another neuro program disappointment that raises questions about late-stage neuroscience returns and could reduce pipeline valuation. Alector Alzheimer’s failure
• Negative Sentiment: J.P. Morgan reiterated an underweight rating with a £17 price target, citing limited near-term earnings upgrade potential and dependence on successful launches and pipeline readouts — this downgrades street sentiment and can pressure the stock. JP Morgan underweight

About GSK

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.